PMID- 17430423
OWN - NLM
STAT- MEDLINE
DCOM- 20070613
LR  - 20071115
IS  - 0303-4569 (Print)
IS  - 0303-4569 (Linking)
VI  - 39
IP  - 2
DP  - 2007 Apr
TI  - Bacille Calmette-Guerin intravesical instillation and erectile function: is there 
      a concern?
PG  - 51-4
AB  - The aim of our study was to evaluate the effect of bacille Calmette-Guerin (BCG) 
      therapy on erectile function in a cohort of male patients affected by non-muscle 
      invasive bladder cancer. Thirty male patients undergoing BCG treatment for 
      non-muscle invasive bladder cancer were enrolled in the study. Their mean age was 
      60.4 years. None of the patients had risk factors for erectile dysfunction (ED). 
      All subjects underwent a BCG standard schedule therapy (once weekly instillation 
      for 6 weeks). International Index of Erectile Function (IIEF-5) and International 
      Prostate Symptom score (I-PSS) were addressed to the patients during the 
      treatment schedule (at fourth or fifth instillation) and 1 month after the last 
      instillation. The mean IIEF-5 score was 17.6 +/- 6.7 during therapy and 21.7 +/- 
      2.92 a month after the last instillation (P=0.008). Baseline ED and the 
      association with lower urinary tract symptoms are variables significantly 
      connected with post-treatment results (P=0.016 and 0.00 respectively) whereas the 
      age seems not to be related to ED (P=0.256). No major side effects were recorded. 
      It is concluded that BCG treatment is effective for prophylaxis of non-muscle 
      invasive bladder cancer; however, it may induce a high incidence of ED. Although 
      this effect is transient and reversible, erectile failure is another source of 
      psychological distress that adversely affects the quality of life of men 
      undergoing BCG treatment.
FAU - Sighinolfi, M C
AU  - Sighinolfi MC
AD  - Department of Urology, University of Modena, Modena, Italy. sighinolfic@yahoo.com
FAU - Micali, S
AU  - Micali S
FAU - De Stefani, S
AU  - De Stefani S
FAU - Mofferdin, A
AU  - Mofferdin A
FAU - Ferrari, N
AU  - Ferrari N
FAU - Giacometti, M
AU  - Giacometti M
FAU - Bianchi, G
AU  - Bianchi G
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Andrologia
JT  - Andrologia
JID - 0423506
RN  - 0 (BCG Vaccine)
SB  - IM
MH  - Administration, Intravesical
MH  - Aged
MH  - BCG Vaccine/administration & dosage/*adverse effects
MH  - Carcinoma/*drug therapy
MH  - Erectile Dysfunction/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*prevention & control
MH  - Urinary Bladder Neoplasms/*drug therapy
EDAT- 2007/04/14 09:00
MHDA- 2007/06/15 09:00
CRDT- 2007/04/14 09:00
PHST- 2007/04/14 09:00 [pubmed]
PHST- 2007/06/15 09:00 [medline]
PHST- 2007/04/14 09:00 [entrez]
AID - AND762 [pii]
AID - 10.1111/j.1439-0272.2007.00762.x [doi]
PST - ppublish
SO  - Andrologia. 2007 Apr;39(2):51-4. doi: 10.1111/j.1439-0272.2007.00762.x.